MOUNTAIN VIEW, Calif., Nov. 19 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the quarter ended September 29, 2007. Revenue for the period was $13.6 million, a 47% increase from the $9.2 million reported for the third quarter of 2006. The Company's net loss was $1.2 million or $0.15 per diluted share for the third quarter of 2007 compared with a loss of $1.1 million or a loss of $0.15 per diluted share in the third quarter of 2006. The prior year financial results do not include the AMS/Laserscope aesthetic acquisition completed on January 16, 2007.
Theodore A. Boutacoff, President and CEO stated, "While neither I nor the other members of the board of directors are satisfied with the Company's recent performance, IRIDEX has taken numerous actions that we believe have put the Company back on track. These actions include:
Mr. Boutacoff continued, "This has been a difficult year for IRIDEX, our employees and our shareholders. We have and will continue to take decisive actions to improve operations, to provide value to our customers and to create value for our shareholders. A key area of focus will be addressing remaining issues and challenges relating to our expanded aesthetics business following the Laserscope acquisition."
Revenue for the nine-month period ended September 29, 2007 was $41.4 million compared with the $26.9 million reported for the same period of 2006. Net loss for the nine-month period ended September 29, 2007 was $6.5 million or $0.80 per diluted share compared with a net loss of $2.0 million or a loss of $0.26 per diluted share during the comparable period of 2006.
Ophthalmology sales were $7.9 million for the third quarter of 2007 compared to $8.0 million reported in the third quarter of 2006. Aesthetics sales grew to $5.7 million for the third quarter of 2007, up from $1.3 million for the corresponding quarter in 2006.
During the third quarter of 2007 domestic sales increased 26% to $7.2 million compared to $5.7 million for the third quarter of 2006; and international sales grew 80% to $6.4 million compared to $3.5 million for the third quarter of 2006. International sales are denominated in US dollars except for sales from the Company's subsidiaries in the UK and France, foreign currency fluctuations had no material impact.
Conference Call
IRIDEX management will conduct a conference call later today, Monday, November 19th at 5:00 p.m. EST. Interested parties may access the live conference call via telephone by dialing (800) 218-0713 (US) or (303) 262-2140 (International), or by visiting the Company's website at http://www.iridex.com. A telephone replay will be available beginning on Monday, November 19 through Monday, November 26, 2007 by dialing (800) 405-2236 (US) or (303) 590-3000 (International) and entering Passcode 11102345#. In addition, an archived version of the webcast will be available beginning November 19, 2007 on the Company's website at http://www.iridex.com.
About IRIDEX
IRIDEX Corporation is a leading worldwide provider of therapeutic based laser systems, disposable laser probes and delivery devices to treat eye diseases in ophthalmology and skin disorders in the aesthetics market. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 97 independent distributors into 107 countries. For further information, visit the Company's website at http://www.iridex.com.
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Act of 1934, as amended, relating to the Company's growth strategy and prospects, revenues, gross margins, and earnings, expenses, integrating the aesthetics business acquired from Laserscope and realizing efficiencies and synergies relating thereto, controlling costs, managing cash, and addressing our liquidity and capital resource needs. Actual results could differ materially and adversely from those projected in the forward-looking statements contained in our Quarterly Reports on Form 10-Q and Annual Report on Form 10-K for the fiscal year ended December 30, 2006 filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.
IRIDEX Corporation
Condensed Consolidated Statements of Operations
(In thousands, except per share data)
(unaudited)
Three Months Ended Nine Months Ended
September September September September
29, 30, 29, 30,
2007* 2006 2007* 2006
Sales $13,575 $9,222 $41,390 $26,869
Cost of sales 7,390 4,350 23,412 13,076
Gross profit 6,185 4,872 17,978 13,793
Operating expenses:
Research and development 1,319 1,506 4,636 3,955
Sales, general and administrative 5,920 4,854 21,740 12,651
Total operating expenses 7,239 6,360 26,376 16,606
Income (loss) from operations (1,054) (1,488) (8,398) (2,813)
Legal settlement 0 0 2,500 0
Interest and other income, net (184) 184 (603) 540
Income (loss) before income taxes (1,238) (1,304) (6,501) (2,273)
Benefit from (provision for)
income taxes 0 161 0 293
Net income (loss) ($1,238) ($1,143) ($6,501) ($1,980)
Net income (loss) per common
share - basic & diluted ($0.15) ($0.15) ($0.80) ($0.26)
Shares used in per common share
basic & diluted calculations 8,218 7,758 8,165 7,680
* Includes the impact of FAS123(R).
IRIDEX Corporation
Condensed Consolidated Balance Sheets
(In thousands)
(Unaudited)
September 29, December 30,
2007 2006
Assets (unaudited)
Current Assets:
Cash and cash equivalents $5,795 $21,051
Restricted cash 3,800 -
Accounts receivable, net 8,516 6,052
Inventories 13,250 9,499
Prepaids and other current assets 2,053 1,264
Total current assets 33,414 37,866
Property and equipment, net 1,840 1,087
Goodwill 10,509 -
Other intangibles, net 14,488 -
Other long term debt 299 1,224
Total assets $60,550 $40,177
Liabilities and Stockholders' Equity
Current Liabilities:
Accounts payable $3,552 $1,830
Short term debt 5,110 -
Accounts compensation 1,540 1,517
Accrued expenses 4,435 2,392
Accrued warranty 2,182 866
Deferred revenue 3,977 1,415
Current portion of long term debt 5,311 -
Total current liabilities 26,107 8,020
Stockholders' Equity:
Preferred stock 5 -
Common stock 83 79
Additional paid-in capital 38,500 29,697
Accumulated other comprehensive loss (25) -
Treasury stock (430) (430)
Retained earnings (3,690) 2,811
Total stockholders' equity 34,443 32,157
Total liabilities and stockholders'
equity $60,550 $40,177
Contact: Theodore A. Boutacoff
President and CEO
650-940-4700
SOURCE IRIDEX Corporation
CONTACT: Theodore A. Boutacoff, President and CEO of IRIDEX Corporation,
+1-650-940-4700
Web site: http://www.iridex.com
